Critical reviews in oncology/hematology最新文献_第8页

Management of Hodgkin Lymphoma during pregnancy, review of the literature and description of an homogenous expectative attitude associated with excellent outcome. 妊娠期霍奇金淋巴瘤的治疗、文献综述以及与良好疗效相关的同质化期望态度的描述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-14 DOI: 10.1016/j.critrevonc.2024.104482

Joshua Hagège, Lorea Aguinaga, Hannah Moatti, Roberta Di Blasi, Catherine Thieblemont, Pauline Brice, Loïc Renaud

{"title":"Management of Hodgkin Lymphoma during pregnancy, review of the literature and description of an homogenous expectative attitude associated with excellent outcome.","authors":"Joshua Hagège, Lorea Aguinaga, Hannah Moatti, Roberta Di Blasi, Catherine Thieblemont, Pauline Brice, Loïc Renaud","doi":"10.1016/j.critrevonc.2024.104482","DOIUrl":"10.1016/j.critrevonc.2024.104482","url":null,"abstract":"<div><p>Hodgkin lymphoma (HL) occuring during pregnancy is a rare condition, and management relies on sparse literature. The specificity of pregnancy requires the clinician to take into account the clinical emergency, the stage of the lymphoma, the trimester of pregnancy, and the patient's choices. The main objective is twofold: to limit the risk of toxicity and adverse events for both mother and fetus, without reducing the chances of a successful outcome. Current literature data suggest that the use of ABVD-type polychemotherapy (adriamycin, bleomycin, vinblastine, dacarbazine) is associated with obstetrical events and long-term fetal toxicity. We report here the results of a homogeneous management considering wait-and-see, vinblastine monotherapy and ABVD polychemotherapy options. The outcomes in terms of obstetrical complications, response rate, and overall survival (100 %) reinforce the idea that strategies that do not involve the use of multidrug therapy are possible and are associated with very good results.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"203 ","pages":"Article 104482"},"PeriodicalIF":5.5,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141997091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 201 (2024) 104416] 晚期胃食管癌 III 期随机试验中的替代终点：Crit. Rev. Oncol./Hematol. 201 (2024) 104416]的更正。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-10 DOI: 10.1016/j.critrevonc.2024.104466

Joel Veas Rodríguez , Ana Prieto , Ester Vilaprinyo , Marta Bonet , Marc Diez , Antonieta Salud , Robert Montal

引用次数: 0

The burden of pediatric critical illness among pediatric oncology patients in low- and middle-income countries: A systematic review and meta-analysis 中低收入国家儿科肿瘤患者的儿科危重病负担：系统回顾和荟萃分析》。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-09 DOI: 10.1016/j.critrevonc.2024.104467

Alejandra Gabela , Roelie M. Wösten-van Asperen , Anita V. Arias , Carlos Acuña , Zebin Al Zebin , Eliana Lopez-Baron , Parthasarathi Bhattacharyya , Lauren Duncanson , Daiane Ferreira , Sanjeeva Gunasekera , Samantha Hayes , Jennifer McArthur , Vaishnavi Divya Nagarajan , Maria Puerto Torres , Jocelyn Rivera , Elizabeth Sniderman , Jordan Wrigley , Huma Zafar , Asya Agulnik

{"title":"The burden of pediatric critical illness among pediatric oncology patients in low- and middle-income countries: A systematic review and meta-analysis","authors":"Alejandra Gabela , Roelie M. Wösten-van Asperen , Anita V. Arias , Carlos Acuña , Zebin Al Zebin , Eliana Lopez-Baron , Parthasarathi Bhattacharyya , Lauren Duncanson , Daiane Ferreira , Sanjeeva Gunasekera , Samantha Hayes , Jennifer McArthur , Vaishnavi Divya Nagarajan , Maria Puerto Torres , Jocelyn Rivera , Elizabeth Sniderman , Jordan Wrigley , Huma Zafar , Asya Agulnik","doi":"10.1016/j.critrevonc.2024.104467","DOIUrl":"10.1016/j.critrevonc.2024.104467","url":null,"abstract":"<div><h3>Background</h3><p>Pediatric oncology patients have increased risk for critical illness; outcomes are well described in high-income countries (HICs); however, data is limited for low- and middle-income countries (LMICs).</p></div><div><h3>Methods</h3><p>We systematically searched PubMed, EMBASE, Web of Science, CINAHL and Global Health databases for articles in 6 languages describing mortality in children with cancer admitted to intensive care units (ICUs) in LMICs. Two investigators independently assessed eligibility, data quality, and extracted data. We pooled ICU mortality estimates using random effect models.</p></div><div><h3>Results</h3><p>Of 3641 studies identified, 22 studies were included, covering 4803 ICU admissions. Overall pooled mortality was 30.3 % [95 % Confidence-interval (CI) 21.7–40.6 %]. Mechanical ventilation [odds ratio (OR) 12.2, 95 %CI:6.2–24.0, p-value<0.001] and vasoactive infusions [OR 6.3 95 %CI:3.3–11.9, p-value<0.001] were associated with ICU mortality.</p></div><div><h3>Conclusions</h3><p>ICU mortality among pediatric oncology patients in LMICs is similar to that in HICs, however, this review likely underestimates true mortality due to underrepresentation of studies from low-income countries.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"203 ","pages":"Article 104467"},"PeriodicalIF":5.5,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824002105/pdfft?md5=7bfd42842e40f707c172f42abab6e8dc&pid=1-s2.0-S1040842824002105-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in tumor-infiltrating lymphocytes: Historical insights, contemporary milestones, and future directions in oncology therapy 肿瘤浸润淋巴细胞的研究进展：肿瘤治疗的历史洞察、当代里程碑和未来方向》。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-08 DOI: 10.1016/j.critrevonc.2024.104471

Muhammad Aizaz , Alina Sami Khan , Maria Khan , Elshan Musazade , Guiwen Yang

{"title":"Advancements in tumor-infiltrating lymphocytes: Historical insights, contemporary milestones, and future directions in oncology therapy","authors":"Muhammad Aizaz , Alina Sami Khan , Maria Khan , Elshan Musazade , Guiwen Yang","doi":"10.1016/j.critrevonc.2024.104471","DOIUrl":"10.1016/j.critrevonc.2024.104471","url":null,"abstract":"<div><p>Tumor-infiltrating lymphocytes (TILs) are a subtype of immune cells that infiltrate and accumulate within tumors. Studies proved that TILs can be used as prognostic and predictive markers for cancer patients' responses to immunotherapy. This review explores the modern knowledge of TILs, the challenges and opportunities for utilizing TILs in cancer treatment, such as the rise of therapies under TIL circumstances, the identification of biomarkers for TIL activity, and methods used to isolate and expand TILs for therapeutic use. Ongoing clinical trials and promising results in different cancer types are highlighted, including melanoma, ovarian, and colorectal cancer. This also focuses on ongoing efforts to improve TIL-based therapies by identifying the specific subsets of TILs that are most effective in treating cancer and developing methods to increase the functionality and persistence of TILs in the tumor microenvironment. The article recapitulates the present state TILs therapy, ongoing research, and improvements to its potency.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"202 ","pages":"Article 104471"},"PeriodicalIF":5.5,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141908681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current mRNA-based vaccine strategies for glioma treatment 目前基于 mRNA 的胶质瘤治疗疫苗策略。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-07 DOI: 10.1016/j.critrevonc.2024.104459

Mengqian Mao , Wanchun Yang , Xuefeng Zhang

引用次数: 0

Genomic biology and therapeutic strategies of liver metastasis from gastric cancer 胃癌肝转移的基因组生物学和治疗策略

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-06 DOI: 10.1016/j.critrevonc.2024.104470

Yichao Wang , Guangyu Ding , Chu Chu , Xiang-Dong Cheng , Jiang-Jiang Qin

引用次数: 0

Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer 分子检测对晚期上皮性卵巢癌手术治疗的影响

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-05 DOI: 10.1016/j.critrevonc.2024.104469

Pierre-Emmanuel Colombo , Christophe Taoum , Michel Fabbro , Stanislas Quesada , Philippe Rouanet , Isabelle Ray-Coquard

{"title":"Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer","authors":"Pierre-Emmanuel Colombo , Christophe Taoum , Michel Fabbro , Stanislas Quesada , Philippe Rouanet , Isabelle Ray-Coquard","doi":"10.1016/j.critrevonc.2024.104469","DOIUrl":"10.1016/j.critrevonc.2024.104469","url":null,"abstract":"<div><p>Ovarian carcinoma remains the most lethal gynaecologic malignancy. Half of all high-grade serous ovarian cancers (HGSOCs) have a homologous recombination deficiency (HRD) with regard to the repair of double-strand DNA breaks and are candidate to receive maintenance treatment with PARP inhibitors. While a wealth of literature exists regarding the therapeutic guidance of patients from a medical standpoint, the influence of the HRD status on the surgical outlook has been comparatively limited. In this review, the clinical and biological features of advanced ovarian cancers with BRCA1/2 mutation and/or HRD status are considered with particular reference to their impact on the surgical management and on the medico-surgical sequence. The modification of the surgical indications according to the results of molecular testing in first-line and recurrent settings are discussed.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"202 ","pages":"Article 104469"},"PeriodicalIF":5.5,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824002129/pdfft?md5=bbf6167333daf291f05c64a101faceaf&pid=1-s2.0-S1040842824002129-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting 免疫疗法中的双重药物：揭示抗体药物共轭物在免疫检查点靶向中的作用。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-05 DOI: 10.1016/j.critrevonc.2024.104472

Sruthi Ranganathan , Aswanth Reddy , Alessandro Russo , Umberto Malepelle , Aakash Desai

引用次数: 0

Interconnected influences of tumour and host microbiota on treatment response and side effects in nasopharyngeal cancer 肿瘤和宿主微生物群对鼻咽癌治疗反应和副作用的相互影响

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-03 DOI: 10.1016/j.critrevonc.2024.104468

Eugene Sheng Yao Lim , Yenyi Ong , Yang Chou , Chee Kin Then

{"title":"Interconnected influences of tumour and host microbiota on treatment response and side effects in nasopharyngeal cancer","authors":"Eugene Sheng Yao Lim , Yenyi Ong , Yang Chou , Chee Kin Then","doi":"10.1016/j.critrevonc.2024.104468","DOIUrl":"10.1016/j.critrevonc.2024.104468","url":null,"abstract":"<div><p>This study elucidates the intricate relationship between nasopharyngeal carcinoma (NPC), a significant malignancy predominant in Asia with notable global incidence and mortality rates, and the host microbiota, including those of tumour, nasal, nasopharyngeal, oral, oropharyngeal, and gut communities. It underscores how the composition and diversity of microbiota are altered in NPC, delving into their implications for disease pathogenesis, treatment response, and the side effects of therapies. A consistent reduction in alpha diversity across oral, nasal, and gut microbiomes in NPC patients compared to healthy individuals signals a distinct microbial signature indicative of the diseased state. The study also shows unique microbial changes tied to different NPC stages, indicating a dynamic interplay between disease progression and microbiota composition. Patients with specific microbial profiles exhibit varied responses to chemotherapy and immunotherapy, underscoring the potential for treatment personalisation based on microbiota analysis. Furthermore, the side effects of NPC treatments, such as oral mucositis, are intensified by shifts in microbial communities, suggesting a direct link between microbiota composition and treatment tolerance. This nexus offers opportunities for interventions aimed at modulating the microbiota to alleviate side effects, improve quality of life, and potentially enhance treatment efficacy. Highlighting the dual potential of microbiota as both a therapeutic target and a biomarker for NPC, this review emphasises its significance in influencing treatment outcomes and side effects, heralding a new era in NPC management through personalised treatment strategies and innovative approaches.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"202 ","pages":"Article 104468"},"PeriodicalIF":5.5,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824002117/pdfft?md5=a7cbd545e2dc35c7b5ee63b2dfbaaa41&pid=1-s2.0-S1040842824002117-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141895038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathogenic mechanisms and latest therapeutic approaches for radiation-induced lung injury: A narrative review 辐射所致肺损伤的致病机制和最新治疗方法：综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-03 DOI: 10.1016/j.critrevonc.2024.104461

Sitong Chang , Jincai Lv , Xuanzhong Wang , Jing Su , Chenbin Bian , Zhuangzhuang Zheng , Huiyuan Yu , Jindian Bao , Ying Xin , Xin Jiang

引用次数: 0